In this interview we discuss the STOPCaP trial, a meta-analysis that looked at optimal systemic therapy options for men with metastatic hormone-sensitive prostate cancer.
Claire Vale, PhD
Advertisement
Articles by Claire Vale, PhD
Advertisement
Latest Updated Articles
Optimal Therapies for Metastatic Hormone-Sensitive Prostate CancerPublished: October 28th 2017 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
2
FDA Grants Fast Track Designation to MT-125 in Glioblastoma
3
HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma
4
FDA Accepts NDA for New Nilotinib Formulation in CML
5
